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Background/aim: Acute exacerbations and chronic inflammation are risk factors for cardiovascular disease (CVD) in cystic fibrosis
(CF) patients. The aim of this study was to investigate the effects of acute exacerbation therapy on arterial stiffness in children with CF.
Materials and methods: Augmentation index (Aix) and pulse wave velocity (PWV) were measured before and after treatment and
1 month after the end of treatment in patients with acute exacerbation. The relationship between hemodynamic measurements and
c-reactive protein (CRP) and pulmonary function tests (PFTs) was investigated.
Results: Measurements before and after treatment were evaluated in 27 patients and were repeated in 21 patients who were clinically
stable 1 month following acute exacerbation. There was a significant decrease in CRP and an increase in spirometry parameters after
treatment. While no significant difference was found between PWV (P = 0.33), a significant difference for Aix before (41.95 ± 12.96%)
and after (30.95 ± 11.47%) treatment and before treatment and stable clinical condition (34.19 ± 14.36%) was obtained (P =0.00, and
P =0.01, respectively). No significant difference in heart rate and other hemodynamic measurements was found. Pretreatment Aix is
associated with poor clinical condition (PFTs, BMI, and clinical score) and systemic inflammation (CRP) (P <0.05).
Conclusion: The decrease of arterial stiffness (Aix) with acute exacerbation treatment in children with CF has been demonstrated. This
result shows that systemic inflammation in CF may cause an increase in arterial stiffness and recurrent exacerbations may increase the
risk of CVD.
Key words: Cystic fibrosis, arterial stiffness, pulse wave velocity analysis, augmentation index, pulmonary exacerbation

1. Introduction
Cystic fibrosis (CF) is a chronic progressive lung disease
with systemic inflammation. Although there is an
increased risk of cardiovascular disease (CVD) in chronic
inflammatory lung and systemic inflammatory diseases
(chronic obstructive pulmonary disease, rheumatoid
arthritis, systemic vasculitis, inflammatory bowel disease,
etc.), there is no clear evidence of CVD incidence in CF
patients [1–3]. In a study by Hull et al. [4], it was shown
that the presence of systemic inflammation in CF patients
may cause vascular changes (increased arterial stiffness)
and CVDs may be seen more frequently with prolonged
survival. Also, systemic inflammation in patients is
thought to cause impaired endothelial function, leading to
an increase in arterial stiffness.

Augmentation index (Aix) and pulse wave velocity
(PWV) are frequently used methods to evaluate arterial
stiffness in recent years. They provide an early assessment
of changes in the structure and function of large arteries
and predict cardiovascular events [5]. These noninvasive
and reproducible measurements are used to evaluate
cardiovascular events and risk factors in many diseases
such as CF.
The increase in CVD risk in chronic obstructive
pulmonary disease exacerbation is related to the severity
of respiratory tract infection and an increase in systemic
inflammation [6]. In the study on vascular changes in acute
exacerbation in adult CF patients, Aix was compared in
exacerbation and after antibiotic treatment, and a significant
reduction in Aix was demonstrated with treatment [7].
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Our previous study demonstrated increased arterial
stiffness in children with CF compared to healthy controls
of similar age and sex. Although patients did not have
common traditional risk factors (increased cholesterol
and low-density lipoprotein, hypertension, and obesity),
increased arterial stiffness was identified [8]. Acute
exacerbations and chronic inflammation are risk factors for
CVD in CF. This study aimed to investigate atherosclerosis
and CVD in CF patients with acute pulmonary
exacerbation. Of the markers of atherosclerosis, Aix, and
pulse wave velocity (PWV) are associated with increased
risk of CVD in acute exacerbation with increased systemic
inflammation in CF. We hypothesized that there would be
a decrease in hemodynamic measurements (risk of CVD)
with a decrease in systemic inflammation with treatment
and an increase in hemodynamic measurements with
preincrement of the inflammation after treatment.
2. Materials and methods
2.1. Study design
The present study is an observational study using the
general management in the Division of Pulmonology. All
subjects provided written informed consent and the study
was approved by the Local Research Ethics Committee
(19-1T/41).
The study included patients between 3 and 18 years
old who were followed up with the diagnosis of CF in the
Ege University Pediatric Pulmonology Department and
diagnosed with acute pulmonary exacerbation between
January 15, 2019 and June 30, 2019.
Patients who received antibiotic therapy for acute
respiratory infection within 1 month, had pulmonary
hypertension, required oxygen and continuous oxygen
supply during infection, noninvasive mechanical
ventilation, and systemic steroid treatment were excluded.
CF-related diabetes was an exclusion factor because of one
of the most important risk factors for the development of
the cardiovascular disease.
Hemodynamic measurements were performed before
and after treatment and 1 month after the end of treatment
(clinically stable period) in patients who were planned for
exacerbation treatment. C-reactive protein (CRP), fasting
blood sugar, and pulmonary function tests (PFT) were
evaluated from medical records and their relationship
with hemodynamic measurements were evaluated.
Bodyweight (kg) and height (cm) were measured.
Body mass index (BMI) was calculated by weight (kg)/
height (m2) formula. Measurements were reported as
z-scores [9]. Shwacman–Kulczycki Score (SKS) was used
to evaluate the clinical status of the patients [10]. The SKS
calculated at the last visit in which patients were clinically
stable was recorded from the medical records.
In our unit, the diagnosis of acute exacerbation in CF
is based on anamnesis (increased cough, new or increased
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productive cough, change in sputum, hemoptysis,
dyspnea, chest pain, and anorexia), physical examination
(fever (body temperature > 38 °C), tachypnea, tachycardia,
hypo-/hypertension, weight loss), laboratory findings
(white blood cell, CRP), pulmonary function tests (>10%
decrease in FEV1 and FVC). Intravenous antibiotic
therapy decision is based on the antibiotic susceptibility
of the microorganism produced in the previous sputum,
induced sputum, throat, or bronchoalveolar lavage culture.
According to the experience of the clinician, appropriate
antibiotic therapy is initiated in patients without previous
microorganism growth. Antibiotic treatment is often
applied for 10–14 days for the causative or suspected
microorganism.
Pulmonary function tests were performed by
spirometry (Flowhandy ZAN 100, Germany) in accordance
with American Thoracic Society standards. Forced vital
capacity (FVC), forced expiratory volume in 1 s (FEV1)
and flow rate in the middle of forced expiration (FEF25-75)
were calculated as percent predicted values. The results
of the patients who underwent PFTs for the diagnosis
of acute exacerbation and the evaluation of treatment
response were examined.
2.2. Hemodynamic measurements
Measurements were performed 2 h after food intake
and before inhaler therapy (short-acting beta-2 agonist,
dornase alpha, and inhaled antibiotics). All hemodynamic
measurements were made under similar conditions (food
intake, inhaler use, time of administration). Because of
technical problems that may occur in hemodynamic
measurements in individuals under 3 years old, patients
over 3 years old were included.
Arterial stiffness measurements were performed in
a quiet room while the patient had been resting for 15
min, in a sitting position. Mobil-O-Graph 24 h PWA
Monitor (IEM GmbH, Stolberg, Germany) was used for
the measurement. An appropriate cuff was chosen for the
measurement of the brachial artery with the oscillometric
method. A Bluetooth connection was established between
the device and the software program developed for data
analysis (Hypertension Management System; ClientServer Company, Stolberg, Germany; IEM GmbH).
Age, sex, height, weight, and smoking information were
entered into the software program. PWV analysis was
performed three times at 5-min intervals. The data were
classified as high-quality and low-quality by the software
program. Only high-quality data were evaluated. The
calculated pulse wave analysis was defined as aortic pulse
wave. Aix heart rate was normalized to 75 beats/min to
avoid interindividual variability secondary to heart rate.
Measurements were performed by staff specifically trained
in the technique and blinded to the clinical characteristics
of each subject.
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2.3. Statistical analysis
For statistical evaluation, the data were analyzed with
SPSS version 20.0 software. Descriptive data were
expressed as mean ± SD if analyzed with parametric tests
and median (min–max); if analyzed with nonparametric
tests, categorical variables were expressed by frequency
and percentage. The Shapiro–Wilk test was used for the
evaluation of normal distribution. A paired t-test was
applied in parametric condition and the Wilcoxon test
was used in nonparametric conditions in comparison of
2 repeated measurement data before and after treatment.
Three repeated measurement data collected before
treatment, after treatment, and during a stable period
were compared with repeated measure ANOVA test.
The correlation between Aix and PFTs and CRP were
carried out by using the Pearson correlation if parametric
test criteria were satisfied and by using the Spearman
correlation analysis if not. In all comparisons, P < 0.05 was
accepted as the limit of statistical significance.
3. Results
Antibiotic treatment was initiated in 32 patients due to
acute exacerbation. Four patients who needed oxygen and
one patient from whom measurement could not be taken
were excluded. Twenty-seven patients with hemodynamic
measurements completed were included in the study.
Demographic data of the patients are presented in Table 1.
Of the patients, 40.7% (n = 11) had inhaled shortacting beta-2 agonists and inhaled steroids, and 73.9% (n =
17) had inhaled antibiotic therapy. There were no patients
on macrolide antibiotics. All patients were using dornase
alpha inhaled therapy.
3.1. Acute exacerbation
The median duration of treatment was 14 (10–21)
days. Microorganisms causing acute exacerbation
were Staphylococcus aureus in 15 (55.5%) patients,
Pseudomonas aeruginosa in 22 (81.4%) patients,
Escherichia coli in 4 (14.8%) patients, Aspergillus spp in 2
(7.4%) and Haemophilus influenza nontype b in 2 (% 7.4)
patients. Beta-lactam/lactamase group antibiotics were
administered to 4 (14.8%) patients, cephalosporin to 6
(22.2%), carbapenem to 8 (29.6%), aminoglycoside to 20
(74%), glycopeptide to 11 (40.7%), fluoroquinolone to 9
(33.3%) patients, and antifungal therapy was initiated in 4
(14.8%) patients.
There was no patient with fever during the
measurements. No significant difference between
peripheral oxygen saturation (SpO2) 
before and after
treatment was found (P > 0.05). While there was no
statistically significant difference between systolic and
diastolic blood pressures, a significant decrease in heart rate
after treatment was noticed (P < 0.05). The CRP reduced
after treatment (P < 0.01). Fasting blood glucose was

Table 1. Clinical characteristics of the patients with CF.
n = 27
Age (months) (median (min–max))

100 (36–211)

Sex (F/M)

16 (59.3) / 11 (40.7)

Z-score of weight (mean ± SD)

–1.58 ± 1.70

Z-score of height (mean ± SD)

–0.19 ± 1.97

Z-score of BMI (mean ± SD)

–2.34 ± 2.56

Mutation, n (%)
F508del homozygous

10 (37)

F508del heterozygous

8 (29.6)

Others

9 (33.3)

Colonization, n (%)
+/-

23 (85.2) / 4 (14.8)

Microorganism, n (%)
Pseudomonas aeruginosa

23 (88.4)

Staphylococcus aureus

13 (73.9)

Aspergillus spp

1 (4)

Escherichia coli

3 (13)

Shwachman–Kulczycki scores
(median (min–max))

60 (40–85)

BMI; body mass index, SD; standard deviation

similar before and after treatment (P > 0.05). Spirometry
parameters (FEV1, FVC, and FEF25-75% predicted) showed
a statistically significant increase after treatment (P < 0.05)
(Table 2).
3.2. Hemodynamic measurements
Hemodynamic measurements before and after treatment
were evaluated in 27 patients. There was a statistically
significant difference in Aix before and after treatment
(44.25 ± 13.02% versus 33.48 ± 12.65%) (P < 0.01), but no
significant difference in PWV (4.43 ± 0.37 m/s versus 4.40
± 0.41 m/s) (P = 0.64).
Measurements were repeated in 21 patients who were
clinically stable 1 month following acute exacerbation.
While no statistically significant difference was found
between PWV (P > 0.05), a statistically significant difference
for Aix before and after treatment (P < 0.05), and before
treatment and stable clinical condition (P < 0.05) was
obtained (Figure). No statistically significant difference
in heart rate and other hemodynamic measurements was
found (P > 0.05) (Table 3).
A significant positive correlation between pretreatment
Aix and CRP (r = 0.40, P = 0.03), and a negative correlation
between pretreatment Aix and FEV1% predicted (r =
–0.74, P < 0.001), FVC% predicted (r = –0.73, P = 0.001)
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Table 2. Subject characteristics, pulmonary function tests, and laboratory measurements
before and after treatment N: 27.
Before treatment
mean ± SD

After treatment
mean ± SD

P**

Heart rate (bpm)

109.88 ± 24.24

99.29 ± 18.77

<0.050

Systolic BP (mm/Hg)

111.22 ± 12.50

108.96 ± 12.40

0.180

Diastolic BP (mm/Hg)

64.11 ± 11.52

63.29 ± 12.03

0.710

CRP (mg/dL)

1.80 (0.03-15.44)*

0.30 (0.03-3.77)*

<0.001***

Glucose (mg/dL)

92.00 ± 14.69

88.14 ± 13.57

0.230

FEV1, %

59.38 ± 24.01

73.27 ± 28.26

<0.001

FVC, %

56.22 ± 20.09

67.36 ± 24.19

<0.001

FEF25-75, %

65.50 ± 43.62

81.38 ± 44.80

0.020

Spirometry N:18

BP; blood pressure, CRP; c reactive protein, FEV1; forced expiratory volume in 1 second,
FVC; forced vital capacity, FEF25-75; forced expiratory flow during the middle half of
FVC, SD; standard deviation, *median (min–max) for nonparametric distribution,
**paired t-test, ***Wilcoxon test

and FEF25-75% predicted (r = –0.56, P = 0.01) was found.
There was no statistically significant correlation between
age and hemodynamic measurements and changes in
hemodynamic measurements before and after treatment
(P > 0.05). Pretreatment Aix was correlated with a poor
clinical condition (SKS) (r = –0.56, P = 0.002) and BMI
z-score (r = –0.51, P = 0.006) before exacerbation. The
change in Aix before and after treatment was not correlated
with changes in CRP and PFTs (P > 0.05). The change in
Aix was correlated with pretreatment Aix (r = –0.51, P
= 0.006), FEV1% predicted (r = 0.55, P = 0.01), FVC%
predicted (r = 0.55, P = 0.01) and SKS (r = 0.40, P = 0.03).
4. Discussion
The decrease of arterial stiffness (Aix) with acute
exacerbation treatment in children with CF has been
demonstrated in the present study. This result shows that
systemic inflammation in CF may cause an increase in
arterial stiffness and recurrent pulmonary exacerbations
may increase the risk of CVD. Furthermore, this is the
first study to demonstrate increased arterial stiffness and
associated risk of CVD in children with CF during acute
exacerbations. Increased arterial stiffness is associated with
poor clinical condition (PFTs, BMI, and clinical score) and
systemic inflammation (CRP).
Recent studies have shown an increased risk of
CVD in chronic diseases associated with systemic
inflammation [2,11]. Even in acute infections with
increased inflammation, transient increases in the risk of
CVD have been reported [12]. The mechanism by which
systemic inflammation causes vascular changes is not fully
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known. Both localized airway inflammation and chronic
systemic inflammation occur in CF. Increased circulating
cytokines and chemokines, acute phase reactants are
responsible for systemic inflammation [13]. Continuous
polymorphonuclear cell (PMN) activation by recurrent
pulmonary infections causes the release of granular
myeloperoxidase (MPO). MPO has been shown to cause an
increase in circulating proinflammatory cytokines [14,15].
In addition, PMNs activated during exacerbations give rise
to an increase in reactive oxygen species (ROS). All these
systemic inflammatory effects and increased oxidative
stress are thought to cause changes in vascular functions
[14]. Increased markers of systemic inflammation and
ROS products in acute exacerbations have been shown to
decrease with treatment [16]. Although there is a decrease
in inflammation products with intensive treatment, there
is no complete improvement due to chronic inflammation
[17]. In this study, in agreement with this information, Aix
has been shown to decrease with systemic inflammation
after acute exacerbation treatment. In a study of adult
population, evaluating the effects of acute exacerbation
treatment on hemodynamic measurements and CVD
risk in CF patients, a statistically significant decrease in
Aix (10.9 ± 10.9% versus 8.1 ± 10.9%) with improvement
in clinical status and PFTs was shown with treatment.
However, the change in hemodynamic measurements after
the termination of the efficacy of treatment has not been
studied [7]. To the best of our knowledge, there are no
other studies of similar design. In this study, it is thought
that there could be an increase in Aix due to chronic
inflammation continuing after treatment. Although
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Figure. Augmentation index (Aix, %) before treatment, after treatment, and in
clinically stable period.
Table 3. Hemodynamic measurements before treatment, after treatment, and in clinically stable period
N: 21.
Before treatment
mean ± SD

After treatment
mean ± SD

Stable
mean ± SD

P*

107.81 ± 5.31

98.09 ± 4.35

99.14 ± 5.12

0.790

SBP (mm/Hg)

112.66 ± 12.65

109.14 ± 13.23

110.33 ± 13.53

0.310

DBP (mm/Hg)

64.14 ± 9.54

62.90 ± 11.51

67.14 ± 8.74

0.180

PP (mm/Hg)

48.52 ± 11.03

46.23 ± 11.36

43.19 ± 10.86

0.200

MAP (mm/Hg)

86.42 ± 9.56

83.95 ± 10.88

86.66 ± 9.84

0.250

SBP (mm/Hg)

97.57 ± 11.43

94.90 ± 11.89

99.04 ± 12.83

0.200

DBP (mm/Hg)

66.09 ± 9.44

64.90 ± 11.43

68.85 ± 8.84

0.210

PP (mm/Hg)

Heart rate (bpm)
Peripheral

Central

31.47 ± 7.80

30.00 ± 8.37

30.19 ± 9.42

0.790

AP (mm/Hg)

7.00 ± 3.60

5.76 ± 3.74

7.14 ± 5.12

0.440

Aix (%)

41.95 ± 12.96

30.95 ± 11.47

34.19 ± 14.36

0.010

PWV (m/s)

4.48 ± 0.39

4.39 ± 0.44

4.50 ± 0.47

0.330

Aix; augmentation index, AP; augmented pressure, DBP; diastolic blood pressure, MAP; mean arterial
pressure, PP; pulse pressure, PWV; pulse wave velocity, SBP; systolic blood pressure SD; standard
deviation. *repeated measure ANOVA

the hemodynamic measurements of the patients in the
stable clinical period were increased, that change was not
statistically significant. That insignificance might have
stemmed from remeasurement shortly after infection.
Hence, a statistically significant increase might also be
observed with measurements taken after a longer period.
Increased arterial stiffness is an independent risk
factor for CVD. Studies have been conducted and used
to evaluate CVD risk in several diseases. Arterial stiffness
can be determined by aortic PWV, the direct measurement

method, or by Aix, the measurement of the composition
of complex and wave reflections [18,19]. Arterial stiffness
and wave reflections are affected differently by age and
various clinical conditions. In this study, there was no
statistically significant correlation between age and
hemodynamic measurements. The different clinical
conditions and severity of infection of the patients may
cause this condition. Age-related changes were more
prominent in PWV for individuals over the age of 50, and
in Aix for individuals under the age of 50 [20]. In a study
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conducted in patients with rheumatoid arthritis over 50
years, PWV was found to be significantly higher than in
healthy controls, whereas, in another study performed
in patients under 50 years, PWV was similar while Aix
were significantly higher than healthy controls [21,22].
Consistent with this information, in our study of pediatric
patients, no statistically significant change was found
in PWV after treatment and a significant change was
obtained in Aix.
Treatment strategies for systemic inflammatory
diseases are planned to reduce inflammation. The risk
of CVD has been observed to reduce with the decrease
of inflammation [23]. Even in healthy individuals, acute
phase reactants such as CRP are predictive markers for
CVD [24]. In a study of patients with systemic vasculitis,
PWV, Aix, and CRP were found to be significantly
higher in the active disease group compared to healthy
controls. Hemodynamic measurements showed a positive
correlation with CPR. While Aix was significantly higher
in active disease than in remission patients, PWV was
shown to be similar [25]. In a study, hemodynamic
measurements of CF patients were compared with those
of healthy controls, and Aix was found to be higher in
CF patients and it was found to be positively correlated
with CRP. In another study examining the change in
hemodynamic measurements with acute infection
treatment, no correlation was found between the change in
Aix and change in CRP after treatment [4,7]. In the present
study, there was a significant positive correlation between
pretreatment Aix and CRP (r = 0.40, P = 0.03). There was
no statistically significant correlation between the change
in Aix and CRP before and after treatment (P > 0.05).
The decrease in arterial stiffness after treatment of
acute exacerbation can be explained by improvement in
clinical status with a decrease in systemic inflammation
and improvement in PFTs. In a study examining the
effects of atorvastatin on arterial stiffness in patients with
rheumatoid arthritis, a significant reduction in arterial
stiffness was demonstrated after 6 weeks of treatment.
The greatest change in Aix has been reported in patients
with high scores of disease activity [26]. In another study
investigating the effect of antitumor necrosis factor-alpha
on arterial stiffness, a significant decrease in aortic PWV
was observed together with the decrease in disease activity
score and inflammation markers (CRP and erythrocyte
sedimentation rate) after 12 weeks of treatment [21].
Pulmonary function tests play an important role in
determining the severity of acute exacerbation and lung
injury in CF. FEV1 provides information on the severity
and clinical status of the disease. The Shwachman–
Kulczycki score is a scoring system used to monitor
the severity of the disease, especially in patients with
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pulmonary dysfunction. There was a significant negative
correlation between pretreatment Aix and PFTs and a
positive correlation between pretreatment Aix and CRP.
Pretreatment Aix was associated with a poor clinical
condition and BMI before exacerbation. The mean increase
in FEV1% predicted after antibiotic treatment was 14.22%.
The change in Aix was associated with pretreatment Aix
(r = –0.51, P = 0.006), FEV1% predicted (r = 0.55, P =
0.01), FVC% predicted (r = 0.55, P = 0.01) and SKS (r =
0.40, P = 0.03). Although the mechanisms of action that
may cause a decrease in Aix have not been studied in the
study, a decrease in inflammation, an increase in PFTs,
and improvement in clinical conditions are thought to be
potentially effective.
4.1. Limitations
This study aimed to investigate the changes in
hemodynamic measurements in acute exacerbation in
children with CF. The mechanisms of action that could
lead to changes in hemodynamic measurements were not
evaluated.
Antibiotic decision and treatment duration were
decided based on the microorganism that cause or is
thought to cause infection, and the clinician’s experience.
It should be kept in mind that the choice of empirical
treatment in patients with unknown etiology may affect
the change in hemodynamic measurements. In addition,
the effect of antibiotic changes and treatment duration
made by the clinician according to culture results and
clinical response on hemodynamic measurements was
not examined. The standard treatment regimens for
future studies should be determined considering all these
differences.
Pulmonary function tests were performed in small
number of patients due to patient-related factors, technical
problems and the high proportion of patients at a young
age in 1 month after the treatment of acute exacerbation.
Therefore, the relationship between hemodynamic
measurements and PFTs were not discussed.
In conclusion, this is the first study to investigate the
effects of acute exacerbation treatment on vascular changes
and CVD risk in children with CF. Here hemodynamic
measurements have been shown to decrease with
antibiotic treatment. Prevention and treatment of acute
exacerbations in childhood may reduce the risk of CVD
in patients. Large-scale, prospective studies are required
to evaluate the effects of vascular changes emerging in
childhood on CVD in further ages. In addition, our study
shows that hemodynamic measurements are related
to parameters (SKS, PFTs, and BMI, etc.) used in the
evaluation and follow-up of patients with CF. This study
may be a pioneering study for the use of hemodynamic
measurements in the routine follow-up of these patients.
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